Abstract 986 Percutaneous Left Atrial Appendage Closure using a novel LAmbre occluder in patients with atrial fibrillation, updated data from FAFA institutional registry study

Background: The Lambre is a new two-structural occluder for percutaneous left atrial appendage closure (LAAC). The novel design of the device includes: occluder with double stabilization system, slimmer delivery sheath, and size-adaptive cover.

Objective: To report updated institutional experience in implantation of the LAmbre occluder in patients with AF.

Methods: All patients indicated to LAAC and implanted with the LAmbre occluder were consecutively included in our institutional registry. The devices were implanted under fluoroscopic and/or trans-esophageal echocardiographic guidance. Clinical follow-up was scheduled at 6 weeks, and thereafter every 6 months post implantation.

Results: A total of 94 patients (mean age 76±12 years, female 43%) were analyzed. The mean CHA2DS2-VaSc was 4±1.4, and the mean HAS-BLED score was 3.5±1.2. Patients with chicken-wing LAA morphology was 76.6%. Mean LAA size was 21±4mm, and mean device size was 26±5mm. The implant success rate was 100%, and of them 61.7% of the patient without needing reposition. The mean fluoroscopic time and procedure time were 3.3±1.8min and 30±10 min. Three (3.2%) peri-procedural adverse events were observed including 1 death, 1 pericardial effusion, and 1 device dislodgement. During 6 months clinical follow-up, 1 (1.1%) patient had device thrombosis, and 1 (1.1%) patient had stroke event.

Conclusion: As a novel LAA occluder, the LAmbre shows favorable implant performance and low incidence of complications.

Clin Res Cardiol (2021) DOI DOI https://doi.org/10.1007/s00392-021-01843-w
Percutaneous Left Atrial Appendage Closure using a novel LAmbre occluder in patients with atrial fibrillation, updated data from FAFA institutional registry study
S. Chen¹, B. Schmidt², K. R. J. Chun³
¹Medizinische Klinik III - CCB, Agaplesion Markus Krankenhaus, Frankfurt am Main; ²CCB im AGAPLESION MARKUS KRANKENHAUS, Frankfurt am Main; ³Medizinisches Versorgungszentrum, CCB am AGAPLESION BETHANIEN KRANKENHAUS, Frankfurt am Main;
Background: The Lambre is a new two-structural occluder for percutaneous left atrial appendage closure (LAAC). The novel design of the device includes: occluder with double stabilization system, slimmer delivery sheath, and size-adaptive cover. Objective: To report updated institutional experience in implantation of the LAmbre occluder in patients with AF. Methods: All patients indicated to LAAC and implanted with the LAmbre occluder were consecutively included in our institutional registry. The devices were implanted under fluoroscopic and/or trans-esophageal echocardiographic guidance. Clinical follow-up was scheduled at 6 weeks, and thereafter every 6 months post implantation. Results: A total of 94 patients (mean age 76±12 years, female 43%) were analyzed. The mean CHA2DS2-VaSc was 4±1.4, and the mean HAS-BLED score was 3.5±1.2. Patients with chicken-wing LAA morphology was 76.6%. Mean LAA size was 21±4mm, and mean device size was 26±5mm. The implant success rate was 100%, and of them 61.7% of the patient without needing reposition. The mean fluoroscopic time and procedure time were 3.3±1.8min and 30±10 min. Three (3.2%) peri-procedural adverse events were observed including 1 death, 1 pericardial effusion, and 1 device dislodgement. During 6 months clinical follow-up, 1 (1.1%) patient had device thrombosis, and 1 (1.1%) patient had stroke event. Conclusion: As a novel LAA occluder, the LAmbre shows favorable implant performance and low incidence of complications.
https://dgk.org/kongress_programme/jt2021/aP68.html